News

BiOrion Technologies receives a EUROSTARS grant for their € 1.7 M colorectal cancer imaging program COLOSELECT

December 11, 2020

 

Groningen, The Netherlands, December 11, 2020

 

The EUROSTARS grant of a EUR 1.7 million colorectal cancer imaging program is awarded to a multidisciplinary consortium including BiOrion Technologies BV, The Netherlands.

EUROSTARS is a joint program between EUREKA and the European Commission, co-funded from the national budgets of 36 EUROSTARS Participating States and Partner Countries and by the European Union through Horizon 2020. The subsidy is for a three-year period and will allow clinical development of PDGF beta receptor binding single domain antibodies conjugated to PET-imaging and therapeutic radionuclides and to target fibrotic stroma in advanced colorectal cancer.

 

Herman Steen, CEO of BiOrion, “We are delighted with the recognition and support for our PDGF beta receptor binding single domain antibodies targeting program by EUROSTARS. This strong and synergistic consortium will enable BiOrion to progress clinical development of our novel targeted imaging diagnostics and therapeutics against fibrotic stroma of solid cancers.”

 

About BiOrion Technologies

BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion PET-imaging diagnostics for fibrotic diseases. These diseases include cardiac, hepatic, pulmonary and kidney fibrosis, among many others, and fibrosis-associated cancers such as colorectal cancer. BiOrion’s platform and drug development engine is based on proprietary PDGF-ß-receptor binding peptides and single domain antibodies that act as targeting vehicles for diagnostic PET radionuclides, therapeutic radionuclides and (existing) anti-fibrotic therapeutics.

 

 

Contact

 

For BiOrion Technologies BV:

Herman Steen, PhD

CEO BiOrion Technologies BV

herman.steen@biorion.com

 

 

First patient enrolled in a PET-imaging study with BiOrion’s 68-Gallium labeled PDGF beta receptor binding bicyclic peptide BOT5035 in patients with organ fibrosis.

September 30, 2020

 

Groningen, The Netherlands, September 30, 2020

 

BiOrion Technologies announced today that a first fibrosis patient has been enrolled in the first-in-human PET imaging study with 68-Gallium labeled PDGF beta receptor binding bicyclic peptide BOT5035.

Herman Steen, CEO of BiOrion, “The enrollment of the first patient in this PET imaging study is a significant milestone for BiOrion. As the PDGF beta receptor represents a specific biomarker for activated myofibroblasts, it is expected to be a sensitive biomarker for fibrosis activity and therefore for disease monitoring of fibrotic diseases”. “This study will allow us to generate insight in the potential of this receptor for disease monitoring of other fibrotic diseases including cancers with fibrotic stroma, such as colon cancer”.

 

About BiOrion Technologies

BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion PET-imaging diagnostics for fibrotic diseases. These diseases include cardiac, hepatic, pulmonary and kidney fibrosis, among many others, and fibrosis-associated cancers such as colorectal cancer. BiOrion’s platform and drug development engine is based on proprietary PDGF-ß-receptor binding peptides and single domain antibodies that act as targeting vehicles for diagnostic PET radionuclides, therapeutic radionuclides and (existing) anti-fibrotic therapeutics.

 

 

Contact

 

For BiOrion Technologies BV:

Herman Steen, PhD

CEO BiOrion Technologies BV

herman.steen@biorion.com

 

 

 

BiOrion concluded investment by a consortium of investors including Pharma Connect Capital

PRESS RELEASE

 

Groningen, The Netherlands, February 7, 2019

 

 

BiOrion Technologies BV has raised funding from a consortium of two existing and one new investor for its further clinical validation programs in fibrosis and fibrotic cancers.

 

BiOrion Technologies BV (BiOrion), a biopharmaceutical drug discovery company, develops products for the diagnosis and treatment of fibrosis and fibrotic cancers. Fibrosis is the consequence of chronic cycles of tissue injury and repair, leading to the accumulation of scar tissue in affected organs and disruption of normal tissue architecture and function. Fibrosis is the final common pathway in virtually all forms of chronic organ failure e.g. liver, lungs and kidneys, ultimately leading to organ transplantation or death. Similar fibrosis mechanisms appear in some solid cancers, that are aggressive and frequently metastasize and show strict dependence on fibrosis-rich stroma.

 

BiOrion has raised additional capital from new investor Pharma Connect Capital, existing investor Carduso Capital and the Management Team for the clinical validation of its proprietary drug-targeting technology. In drug targeting, drugs are delivered specifically to cells that cause the disease and not to the healthy cells. Thus, such therapy will be more effective with fewer side effects. The most recent targeting technology of BiOrion is developed in house. This new technology provides opportunities to develop both high affinity binding drugs as well as imaging diagnostics for fibrosis, based on the same technology platform. The clinical validation study is scheduled for the next few years, allowing targeted therapy leading to fibrosis resolution.

 

 

About BiOrion

 

BiOrion is a Dutch biopharmaceutical drug discovery company involved in developing targeted therapeutics and companion imaging diagnostics for myofibroblast-associated diseases, such as hepatic fibrosis, renal fibrosis, cardiac fibrosis, idiopathic pulmonary fibrosis and fibrosis-associated cancers such as colorectal cancer.

 

BiOrion’s platform and drug development engine is based on proprietary PDGF-ß-receptor binding peptides and VHH nanobodies. PDGF is one of the main drivers of fibrosis, and its receptor is specifically over-expressed on the key pathogenic cells: the myofibroblasts. This allows cell-specific targeting of diagnostic labels and (existing) antifibrotic drugs. For more information about BiOrion: www.biorion.com.

 

 

About Pharma Connect Capital

 

Pharma Connect Capital is an investment firm based in Groningen, The Netherlands, and invests in early stage drug development, drug delivery technologies, biomarkers and diagnostics. Academic concepts and innovative ideas from pharma & biotech companies are supported by Pharma Connect Capital to reach the initial proof of concept stage. Pharma Connect Capital invests in startup companies located in Groningen, Friesland & Drenthe with a mission to develop new drugs, drug delivery technologies, biomarkers or diagnostics.

For more information on Pharma Connect Capital: www.pharmaconnectcapital.com.

 

 

About Carduso Capital

 

Carduso Capital is an investment firm based in Groningen, The Netherlands that participates in innovative technology companies that have strong technology links with the University of Groningen (RUG) and the University Medical Centre of Groningen (UMCG) and its affiliates. Carduso Capital believes it is important to invest in innovative companies that are early stage or at a certain moment search for capital to finance their growth. Carduso Capital supports initiatives within the main themes Life Sciences and Energy and aims for long-term cooperation’s. Besides participations with capital Carduso Capital also provides proactive management support and the use of its broad international network.

For more information about Carduso Capital: www.cardusocapital.com.

 

BiOrion Technologies receives an EFRO TENDER VALORISATIE 2017 grant for its € 1.0 million cardiac fibrosis imaging program.

 

Groningen, The Netherlands, December 14, 2017

 

An EFRO TENDER VALORISATIE 2017 grant of a EUR 1.0 million cardiac fibrosis imaging program is awarded to BiOrion Technologies BV. The grant will be used for the preparation and execution of a clinical phase 0 imaging study in cardiac fibrosis patients and the preclinical development of a targeted therapeutic, with BiOrion’s PDGF beta receptor binding bicyclic peptide conjugates.

EFRO TENDER VALORISATIE 2017 is a program of the European Regional Development Fund from the European Commission, co-funded from the national budgets of Participating States, Partner Countries and by the European Union through Horizon 2020.

 

Herman Steen, CEO of BiOrion, said “This European Union EFRO grant will further enable BiOrion to progress its clinical development of its novel myofibroblast targeting platform. It is an ongoing recognition and support for our PDGF-beta-receptor binding bicyclic peptide drug-conjugates technology.”

 

About BiOrion Technologies

BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. These diseases include cardiac fibrosis, hepatic fibrosis, and fibrosis-associated cancers such as colorectal cancer. BiOrion’s platform and drug development engine is based on proprietary PDGF-beta-receptor binding bicyclic peptides that act as targeting vehicles for diagnostic PET radionuclides and (existing) anti-fibrotic therapeutics.

 

Contact

Herman Steen, PhD

CEO BiOrion Technologies BV

herman.steen@biorion.com

 

BiOrion Technologies, Zealand Pharma and Akademiska Sjukhuset Uppsala receive a EUROSTARS grant for their € 1.8 M fibrosis imaging program BONIFIB

September 26, 2017

Groningen, The Netherlands, September 26, 2017

 

The EUROSTARS grant of a EUR 1.8 million fibrosis imaging program is awarded to a multidisciplinary consortium including BiOrion Technologies BV, Zealand Pharma A/S and Akademiska Sjukhuset, PET Centre, University Uppsala. EUROSTARS is a joint program between EUREKA and the European Commission, co-funded from the national budgets of 36 EUROSTARS Participating States and Partner Countries and by the European Union through Horizon 2020. The subsidy is for a three-year period and will allow clinical development of a PDGF beta receptor binding bicyclic peptide conjugated to a PET radionuclide to image hepatic fibrosis.

 

Herman Steen, CEO of BiOrion, “We are delighted with the recognition and support for our PDGF beta receptor binding bicyclic peptide drug-targeting program by EUROSTARS. This strong and synergistic consortium will enable BiOrion to progress clinical development of our novel targeted therapeutics against fibrosis, not only in liver.”

 

About BiOrion Technologies
BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. These diseases include cardiac fibrosis and hepatic fibrosis, and fibrosis-associated cancers such as colorectal cancer. BiOrion’s platform and drug development engine is based on proprietary PDGF-ß-receptor binding bicyclic peptides that act as targeting vehicles for diagnostic PET radionuclides and (existing) anti-fibrotic therapeutics.

 

About Zealand Pharma
Zealand Pharma A/S was founded in 1997 and is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand Pharma intends to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other specialty disease areas with significant unmet medical needs.

 

About Akademiska Sjukhuset, PET Centre
Akademiska Sjukhuset is a leading University hospital in Sweden with 8000 employees. The PET Centre at the hospital was created in 1991 and performs about 1900 clinical PET investigations per year including around 350 for clinical research, with 25 different PET tracers. PET Centre performs also research in radiochemistry and preclinical PET.

 

Contact
Herman Steen, PhD
CEO BiOrion Technologies BV
herman.steen@biorion.com

BiOrion Technologies receives a VIA2016 grant for its targeted treatment program in fibrosis.

 

Groningen, The Netherlands, March 13, 2017

 

A VIA2016 grant of a EUR 50 thousand in fibrosis treatment is awarded to BiOrion Technologies BV. The grant will be used for the optimization of targeted interferon gamma in fibrosis with BiOrion’s PDGF beta receptor binding bicyclic peptide program.

Fibrosis is estimated to cause up to 45% of all deaths in the industrial world and rank amongst the top three diseases during the coming decade. Yet, there is currently no effective fibrosis medication available. BiOrion Technologies have developed a platform technology that allows specific detection of fibrotic cells by recognising a protein that is present at high density on a sick cell’s surface. This technology is the basis of our novel anti-fibrotic compound that specifically enters fibrotic cells only, leaving healthy cells unaffected. This improves treatment efficacy and decreases side effects. However, fibrosis is a chronic disease and requires long-term medication. With medicine used for a long time, there is a risk that a patient’s immune system recognises such treatment as foreign and raises an immune reaction against the drug, eventually reducing the medicine efficiency. Here, our aim is to further develop our anti-fibrosis drug by creating a novel variant that closely resemble the body’s own molecules and avoids potential recognition by the immune system. This would further improve the medication’s efficiency and safety.

VIA2016 is a program of the European Regional Development Fund from the European Commission, co-funded from the national budgets of Participating States, Partner Countries and by the European Union through Horizon 2020.

 

 

About BiOrion Technologies

BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. These diseases include cardiac fibrosis, hepatic fibrosis, and fibrosis-associated cancers such as colorectal cancer. BiOrion’s platform and drug development engine is based on proprietary PDGF-beta-receptor binding bicyclic peptides that act as targeting vehicles for diagnostic PET radionuclides and (existing) anti-fibrotic therapeutics.

 

Contact

Herman Steen, PhD

CEO BiOrion Technologies BV

herman.steen@biorion.com

BiOrion Technologies receives a VIA2016 grant for its fibrosis imaging program.

 

Groningen, The Netherlands, March 6, 2017

 

A VIA2016 grant of a EUR 50 thousand in fibrosis imaging  is awarded to BiOrion Technologies BV. The grant will be used for the optimization of PET radio-tracers and optical tracers in fibrosis with BiOrion’s PDGF beta receptor binding bicyclic peptide conjugates.

VIA2016 is a program of the European Regional Development Fund from the European Commission, co-funded from the national budgets of Participating States, Partner Countries and by the European Union through Horizon 2020.

 

 

About BiOrion Technologies

BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. These diseases include cardiac fibrosis, hepatic fibrosis, and fibrosis-associated cancers such as colorectal cancer. BiOrion’s platform and drug development engine is based on proprietary PDGF-beta-receptor binding bicyclic peptides that act as targeting vehicles for diagnostic PET radionuclides and (existing) anti-fibrotic therapeutics.

 

Contact

Herman Steen, PhD

CEO BiOrion Technologies BV

herman.steen@biorion.com

 

BiOrion concluded investment by Carduso Capital

PRESS RELEASE

 

Groningen, The Netherlands, November 11, 2016

 

BiOrion Technologies BV has raised funding from Carduso Capital for its clinical validation program in fibrosis.

BiOrion Technologies BV (BiOrion), a biopharmaceutical drug discovery company, develops products for the diagnosis and treatment of fibrosis. Fibrosis is a consequence of chronic cycles of tissue injury and repair, leading to the accumulation of scar tissue in affected organs and disruption of normal tissue architecture and function. Fibrosis is the final common pathway in virtually all forms of chronic organ failure e.g. liver, lungs and kidneys, ultimately leading to organ transplantation or death.

BiOrion has raised additional capital from Carduso Capital for the clinical validation of its proprietary drug-targeting technology. In drug targeting, drugs are delivered specifically to cells that cause the disease and not to the healthy cells. Thus, such therapy will be more effective with fewer side effects. The targeting technology of BiOrion is based on the research of Prof. Dr. Klaas Poelstra of the University of Groningen. It provides opportunities to develop both drugs as well as imaging diagnostics for fibrosis, based on the same technology platform. The clinical validation study is scheduled for next year, allowing early detection of fibrosis resolution.

 

About BiOrion

BiOrion is a Dutch biopharmaceutical drug discovery company involved in developing targeted therapeutics and companion imaging diagnostics for myofibroblast-associated diseases, such as hepatic fibrosis, renal fibrosis, cardiac fibrosis, idiopathic pulmonary fibrosis and fibrosis-associated cancers such as colorectal cancer.

BiOrion’s platform and drug development engine is based on proprietary PDGF-ß-receptor binding bicyclic peptides. PDGF is one of the main drivers of fibrosis, and its receptor is specifically over-expressed on the key pathogenic cells: the myofibroblasts. This allows cell-specific targeting of diagnostic labels and (existing) antifibrotic drugs. For more information about BiOrion: www.biorion.com

 

About Carduso Capital

Carduso Capital is an investment firm based in Groningen, The Netherlands that participates in innovative technology companies that have strong technology links with the University of Groningen (RUG) and the University Medical Centre of Groningen (UMCG) and its affiliates. Carduso Capital believes it is important to invest in innovative companies that are early stage or at a certain moment search for capital to finance their growth. Carduso Capital supports initiatives within the main themes Life Sciences and Energy and aims for long-term cooperation’s. Besides participations with capital Carduso Capital also provides proactive management support and the use of its broad international network. For more information about Carduso Capital: www.cardusocapital.com